Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer

Chadha, Awalpreet S.; Khoo, Allison; Aliru, Maureen; Arora, Hitesh; Gunther, Jillian R.; Krishnan, Sunil

doi:10.1016/j.semradonc.2016.05.002

Cited by 24 publications

(25 citation statements)

References 208 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the time of diagnosis, the majority of patients with PDAC present with unresectable disease due to locally advanced and/or metastatic disease . In patients with resectable non‐metastatic PDAC, disease recurrence after curative surgery is common and long‐term survival rates are low . Adjuvant therapies have demonstrated efficacy in delaying tumor recurrence and improving survival .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma

Iwasaki

Hiraoka

Ino³

et al. 2019

Cancer Science

View full text Add to dashboard Cite

Neural invasion is one of the malignant features contributing to locally advanced and/or metastatic disease progression in patients with pancreatic ductal adenocarcinoma ( PDAC ). Few studies exist on the distribution and state of nerve fibers in PDAC tissue and their clinicopathological impacts. The aim of the present study was to investigate the clinicopathological characteristics and prognostic value of intrapancreatic neural alterations in patients with PDAC . We retrospectively analyzed 256 patients with PDAC who underwent macroscopic curative surgery. Nerve fibers, immunolabeled with a specific neural marker GAP ‐43, were digitally counted and compared among PDAC , chronic pancreatitis ( CP ) and normal pancreatic tissues. Interlobular nerve fibers were apparently hypertrophic in both CP and PDAC , although intrapancreatic neural density and nerve number decreased characteristically in PDAC . They tended to decrease toward the center of the tumor. Kaplan‐Meier survival analyses revealed a statistically significant correlation between low neural density and shorter overall survival ( OS ) ( P = 0.014), and between high neural invasion and shorter OS ( P = 0.017). Neural density ( P = 0.04; HR = 1.496; 95% CI 1.018‐2.199) and neural invasion ratio ( P = 0.064; HR = 1.439; 95% CI .980‐2.114) were prognostic factors of shorter OS in the multivariate analysis. These findings suggest low intrapancreatic neural density in patients with PDAC as an independent prognosticator, which may represent aggressive tumor behavior. Furthermore, we propose a simple, practical and reproducible method (to measure neural density and the neural invasion ratio during conventional histopathological diagnosis of PDAC ), which has been validated using another cohort (n = 81).

show abstract

Section: Introductionmentioning

confidence: 99%

“…3,4 In patients with resectable non-metastatic PDAC, disease recurrence after curative surgery is common and long-term survival rates are low. 5 Adjuvant therapies have demonstrated efficacy in delaying tumor recurrence and improving survival. 6 However, PDAC patient outcomes have not changed over the past three decades.…”

Section: Introductionmentioning

confidence: 99%

Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma

Iwasaki

Hiraoka

Ino³

et al. 2019

Cancer Science

View full text Add to dashboard Cite

show abstract

“…Pancreatic cancer is the fourth leading cause of cancerrelated death in Japan as well as in Western countries. The 5-year survival rate for patients with pancreatic cancer is less than 5%, and overcoming this poor prognosis remains one of the most formidable challenges in oncology (1,2).…”

Section: Abstract Background: Optimizing Targeting Strategies Formentioning

confidence: 99%

“…Surgical resection is the only curative treatment option but the 5-year survival rate for patients who undergo this procedure is only 15-20%. Advances in neoadjuvant and adjuvant chemotherapeutic regimens have resulted in some improvement in outcome (2)(3)(4). Existing systemic therapies are only modestly effective and the median survival for patients with metastatic disease remains 6 months (2,3,5).…”

Section: Abstract Background: Optimizing Targeting Strategies Formentioning

confidence: 99%

A Tumor-targeting Adenovirus with High Gene-transduction Efficiency for Primary Pancreatic Cancer and Ascites Cells

Nagasato

Rin

Yamamoto

et al. 2017

View full text Add to dashboard Cite

“…Currently, gene therapy has emerged as a major medical breakthrough and a number of researchers have focused on using modern advancements in genetic therapy to treat life-threatening and refractory diseases such as prevention of HIV [9], management of hematological disorders [10], metabolic disorders [11,12], cancer treatment [13,14,15] and stem cell approaches [16]. Since the introduction of gene therapy for dental applications in the 1990s [4], progressive clinical trials are being carried out in humans and on animal models for various applications with promising outcomes.…”

Section: Introductionmentioning

confidence: 99%

Gene Therapy: A Paradigm Shift in Dentistry

Siddique

Raza

Ahmed

et al. 2016

Genes

View full text Add to dashboard Cite

Gene therapy holds a promising future for bridging the gap between the disciplines of medicine and clinical dentistry. The dynamic treatment approaches of gene therapy have been advancing by leaps and bounds. They are transforming the conventional approaches into more precise and preventive ones that may limit the need of using drugs and surgery. The oral cavity is one of the most accessible areas for the clinical applications of gene therapy for various oral tissues. The idea of genetic engineering has become more exciting due to its advantages over other treatment modalities. For instance, the body is neither subjected to an invasive surgery nor deep wounds, nor is it susceptible to systemic effects of drugs. The aim of this article is to review the gene therapy applications in the field of dentistry. In addition, therapeutic benefits in terms of treatment of diseases, minimal invasion and maximum outcomes have been discussed.

show abstract

Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer

Cited by 24 publications

References 208 publications

Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma

Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma

A Tumor-targeting Adenovirus with High Gene-transduction Efficiency for Primary Pancreatic Cancer and Ascites Cells

Gene Therapy: A Paradigm Shift in Dentistry

Contact Info

Product

Resources

About